These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 1975524

  • 1. Beta-blockers, plasma lipids, and coronary heart disease.
    Cruickshank JM.
    Circulation; 1990 Sep; 82(3 Suppl):II60-5. PubMed ID: 1975524
    [Abstract] [Full Text] [Related]

  • 2. The adrenergic system and prevention of myocardial damage by beta-blockade: a clinical overview.
    Cruickshank JM.
    J Cardiovasc Pharmacol; 1989 Sep; 14 Suppl 9():S20-4. PubMed ID: 2483227
    [Abstract] [Full Text] [Related]

  • 3. [Changes in lipids and lipoproteins caused by the beta-blocking agents used as antihypertensives].
    Rouffy J, Chanu B, Bakir R, Sauvanet JP.
    J Pharmacol; 1983 Sep; 14 Suppl 2():183-99. PubMed ID: 6138467
    [Abstract] [Full Text] [Related]

  • 4. Do beta-blockers alter lipids and what are the consequences?
    Holtzman E, Rosenthal T, Goldbourt U, Segal P.
    J Cardiovasc Pharmacol; 1987 Sep; 10 Suppl 2():S86-92; discussion S93. PubMed ID: 2481177
    [Abstract] [Full Text] [Related]

  • 5. Anti-atherosclerotic and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese Macaca fuscata monkeys.
    Miyazaki M, Hosoki K, Okunishi H, Ishii K, Ikeno A, Okazaki Y.
    Arzneimittelforschung; 1994 Mar; 44(3):288-97. PubMed ID: 8192692
    [Abstract] [Full Text] [Related]

  • 6. The emerging problem of plasma lipid changes during antihypertensive therapy.
    Johnson BF.
    J Cardiovasc Pharmacol; 1982 Mar; 4 Suppl 2():S213-21. PubMed ID: 6177959
    [Abstract] [Full Text] [Related]

  • 7. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
    Bakir R, Hilliquin P.
    Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243
    [Abstract] [Full Text] [Related]

  • 8. Alterations in plasma lipids consequent to endurance training and beta-blockade.
    Morton AR, Stanforth PR, Freund BJ, Joyner MJ, Jilka SM, Hartzell AA, Ewy GA, Wilmore JH.
    Med Sci Sports Exerc; 1989 Jun; 21(3):288-92. PubMed ID: 2567483
    [Abstract] [Full Text] [Related]

  • 9. [The Göttingen Risk, Incidence and Prevalence (GRIPS) study. Recommendations for the prevention of coronary heart disease].
    Cremer P, Muche R.
    Ther Umsch; 1990 Jun; 47(6):482-91. PubMed ID: 2375005
    [Abstract] [Full Text] [Related]

  • 10. [Determination of the usefulness of selected biochemical parameters for assessing the advanced atheromatous changes in human coronary arteries].
    Bukowska H.
    Ann Acad Med Stetin; 1998 Jun; 44():29-43. PubMed ID: 9857530
    [Abstract] [Full Text] [Related]

  • 11. Effects of calcium antagonists and adrenergic antihypertensive drugs on plasma lipids and cellular cholesterol metabolism.
    Krone W, Müller-Wieland D, Nägele H, Behnke B, Greten H.
    J Cardiovasc Pharmacol; 1987 Jun; 10 Suppl 10():S199-202. PubMed ID: 2455133
    [Abstract] [Full Text] [Related]

  • 12. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
    Athyros VG, Papageorgiou AA, Avramidis MJ, Kontopoulos AG.
    Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
    [Abstract] [Full Text] [Related]

  • 13. Metabolic changes during antihypertensive therapies.
    Krone W, Nägele H.
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():69-73; discussion 74. PubMed ID: 2575177
    [Abstract] [Full Text] [Related]

  • 14. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z, Mihatov S, Milicić D, Bergovec M, Planinc D, TASPIC-CRO Study Group Investigators.
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [Abstract] [Full Text] [Related]

  • 15. Beta-blockers, dyslipidemia, and coronary artery disease. A reassessment.
    Burris JF.
    Arch Intern Med; 1993 Sep 27; 153(18):2085-92. PubMed ID: 8104394
    [Abstract] [Full Text] [Related]

  • 16. The effects of adrenergic blockade on lipoproteins using the rat as an experimental model.
    Balasubramaniam S, Simons LA, Hickie JB, Chang S.
    Artery; 1990 Sep 27; 17(2):60-70. PubMed ID: 1968740
    [Abstract] [Full Text] [Related]

  • 17. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ, Guérin M, Bruckert E.
    Eur Heart J; 1998 Feb 27; 19 Suppl A():A24-30. PubMed ID: 9519339
    [Abstract] [Full Text] [Related]

  • 18. Effects of oral contraceptives on lipid metabolism.
    Krauss RM.
    J Reprod Med; 1986 Jun 27; 31(6 Suppl):549-50. PubMed ID: 3723487
    [Abstract] [Full Text] [Related]

  • 19. Effect of mepindolol on serum lipids.
    Martignoni A, Perani G, Finardi G, Mastropasqua E, Fogari R.
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov 27; 20(11):543-5. PubMed ID: 7174157
    [Abstract] [Full Text] [Related]

  • 20. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL, Lenz ML, Taylor AA.
    J Hum Hypertens; 1990 Oct 27; 4 Suppl 3():23-33. PubMed ID: 1979819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.